Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

CD40 ligand preferentially modulates immune response and enhances protection against influenza virus.

Hashem AM, Gravel C, Chen Z, Yi Y, Tocchi M, Jaentschke B, Fan X, Li C, Rosu-Myles M, Pereboev A, He R, Wang J, Li X.

J Immunol. 2014 Jul 15;193(2):722-34. doi: 10.4049/jimmunol.1300093. Epub 2014 Jun 13.

2.

Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.

Fan X, Hashem AM, Chen Z, Li C, Doyle T, Zhang Y, Yi Y, Farnsworth A, Xu K, Li Z, He R, Li X, Wang J.

Mucosal Immunol. 2015 Jan;8(1):211-20. doi: 10.1038/mi.2014.59. Epub 2014 Jul 23.

3.
6.

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.

J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27.

PMID:
18789973
7.

Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.

Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ.

J Immunol. 1999 Apr 1;162(7):4163-70.

9.

Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.

Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y, Tan W, Ruan L.

PLoS One. 2012;7(12):e52488. doi: 10.1371/journal.pone.0052488. Epub 2012 Dec 21.

10.

Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response.

Seah SG, Brady JL, Carrington EM, Ng WC, Sutherland RM, Hancock MS, La Gruta NL, Brown LE, Turner SJ, Lew AM, Zhan Y.

J Leukoc Biol. 2013 Jan;93(1):145-54. doi: 10.1189/jlb.0612266. Epub 2012 Oct 29.

PMID:
23108101
11.

Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, Suzuki Y, Aizawa C, Kurata T.

J Immunol. 1996 May 15;156(10):3892-900.

PMID:
8621928
12.

Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections.

Zhong W, Liu F, Dong L, Lu X, Hancock K, Reinherz EL, Katz JM, Sambhara S.

PLoS One. 2010 May 11;5(5):e10583. doi: 10.1371/journal.pone.0010583.

13.

Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection.

Tite JP, Hughes-Jenkins C, O'Callaghan D, Dougan G, Russell SM, Gao XM, Liew FY.

Immunology. 1990 Oct;71(2):202-7.

14.

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.

Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.

Cancer Gene Ther. 2002 Feb;9(2):202-8.

15.
17.

Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.

Fossum E, Grødeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, Henri S, Malissen B, Bogen B.

Eur J Immunol. 2015 Feb;45(2):624-35. doi: 10.1002/eji.201445080. Epub 2014 Dec 28.

19.

Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection.

Wiley JA, Hogan RJ, Woodland DL, Harmsen AG.

J Immunol. 2001 Sep 15;167(6):3293-9.

20.

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.

Tao P, Luo M, Pan R, Ling D, Zhou S, Tien P, Pan Z.

Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9.

PMID:
19135483

Supplemental Content

Support Center